J
Jason Morris
Researcher at Harvard University
Publications - 9
Citations - 2179
Jason Morris is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 4 publications receiving 1227 citations.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
Peter Chen,Ajay Nirula,Barry Heller,Robert L. Gottlieb,Joseph Boscia,Jason Morris,Gregory D. Huhn,Jose Cardona,Bharat Mocherla,Valentina Stosor,Imad Shawa,Andrew C. Adams,Jacob Van Naarden,Kenneth L. Custer,Lei Shen,Michael Durante,Gerard J. Oakley,Andrew E. Schade,Janelle Sabo,Dipak R. Patel,Paul Klekotka,Daniel Skovronsky +21 more
TL;DR: In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11.
Journal ArticleDOI
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Robert L. Gottlieb,Ajay Nirula,Peter Chen,Joseph Boscia,Barry Heller,Jason Morris,Gregory D. Huhn,Jose Cardona,Bharat Mocherla,Valentina Stosor,Imad Shawa,Princy Kumar,Andrew C. Adams,Jacob Van Naarden,Kenneth L. Custer,Michael Durante,Gerard J. Oakley,Andrew E. Schade,Timothy R. Holzer,Philip J. Ebert,Richard E. Higgs,Nicole L. Kallewaard,Janelle Sabo,Dipak R. Patel,Paul Klekotka,Lei Shen,Daniel Skovronsky +26 more
TL;DR: The BLAZE-1 trial as mentioned in this paper evaluated the effect of bamlanivimab monotherapy and combination therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in mild to moderate COVID-19.
Journal ArticleDOI
Photodynamic therapy for endodontic disinfection.
Nikolaos S. Soukos,Peter Shih-Yao Chen,Jason Morris,Karriann Ruggiero,Abraham D. Abernethy,S. Som,Federico Foschi,Stephanie Doucette,Lili Luschke Bammann,Carla Raquel Fontana,Apostolos G. Doukas,Philip Stashenko +11 more
TL;DR: It is concluded that PDT may be developed as an adjunctive procedure to kill residual bacteria in the root canal system after standard endodontic treatment.
Posted ContentDOI
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19
Meghan N. Dougan,M Azizad,P. Chen,Becca Feldman,Matthew B. Frieman,A. Igbinadolor,P. R. Kumar,Jason Morris,Jeffrey A Potts,Lauren Baracco,Lee Macpherson,Nicole L. Kallewaard,Darshna Patel,Matthew M. Hufford,Linda Wietecha,Emmanuel Chigutsa,Sarah Demmon,Britta E. Jones,Ajay Nirula,Daniel Skovronsky,M. Williams,Robert L. Gottlieb +21 more
TL;DR: Safety results were consistent with previous studies investigating mAbs targeting SARS-CoV-2, and patients at high risk for progression to severe COVID-19 received only active therapy without placebo.
Journal ArticleDOI
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
Michael Dougan,Ajay Nirula,Masoud Azizad,Bharat Mocherla,Robert L. Gottlieb,Peter Chen,Corey Hebert,Russell Perry,Joseph Boscia,Barry Heller,Jason Morris,Chad Crystal,Awawu Igbinadolor,Gregory D. Huhn,Jose Cardona,Imad Shawa,Princy Kumar,Andrew C. Adams,Jacob Van Naarden,Kenneth L. Custer,Michael Durante,Gerard J. Oakley,Andrew E. Schade,Timothy R. Holzer,Philip J. Ebert,Richard E. Higgs,Nicole L. Kallewaard,Janelle Sabo,Dipak R. Patel,Matan C. Dabora,Paul Klekotka,Lei Shen,Daniel Skovronsky +32 more
TL;DR: In this paper, the authors showed that patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19) and that vaccine-derived immunity develops over time, neutralizi...